Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study.

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMartin SvatoňMKMagdalena Knetki‐WróblewskaPHPetr Hošek

Discussion

Loading...

Member takes

Overview

Real-world evidence shows pembrolizumab plus chemotherapy improves response rates in NSCLC patients, suggesting a potential approach for better treatment outcomes.

Key Points

  • Patients treated with pembrolizumab plus chemotherapy had a significantly higher response rate compared to those who received pembrolizumab alone.
  • In a study of 793 patients, the combination treatment showed a response rate of p <0.0001, indicating an effective treatment option for aggressive cases.
  • Retrospective analysis from eight oncology centers in Central Europe evaluated treatment data focusing on PD-L1 expression levels and stage IV non-small cell lung cancer.
  • While the combination did not show a survival benefit in overall survival, it suggests that response rate improvements could inform treatment strategies for symptomatic tumors.

Cite This Study

Svatoň et al. (2025) studied this question.

synapsesocial.com/papers/68c23f1fb210217d64795097https://doi.org/10.7150/jca.113815
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact2025
  2. 2First real-world experience with 1L pembrolizumab and chemotherapy treatment for advanced triple-negative breast cancer in Poland: safety analysis and first survival outcomes from a multicenter cohort2025
  3. 3Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice2025 · 3 citations
  4. 4Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)2025
  5. 5The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials2025 · 3 citations